Treatment
Oxygen. To achieve arterial oxygen saturation of a 90% (a 95% in children), oxygen should be administered by nasal cannulae, by mask, or rarely by head box in some infants. PaCO2 may worsen in some patients on 100 percent oxygen, especially those with more severe airflow
Obstruction. Oxygen therapy should be titrated against pulse oximetry to maintain a satisfactory oxygen saturation.
Rapid-acting inhaled ß2–agonists. Rapid-acting inhaled beta2-agonists should be administered at regular intervals. Although most rapid-acting beta2-agonists have a short duration of effect, the long-acting bronchodilator formoterol, which has both a rapid onset of action and a long duration of effect, has been shown to be equally effective without increasing side effects, though it is considerably more expensive.
The importance of this feature of formoterol is that it provides support and reassurance regarding the use of a combination of formoterol and budesonide early in asthma exacerbations. A modestly greater bronchodilator effect has been shown with levabuterol compared to racemic albuterol in both adults and children with an asthma exacerbation. In a large study of acute asthma in children and in adults not previously treated with glucocorticosteroid, levabuterol
treatment resulted in lower hospitalization rates compared to racemic albuterol treatment, but in children the length of hospital stay was no different.
Studies of intermittent versus continuous nebulized shortacting beta2-agonists in acute asthma provide conflicting results. In a systematic review of six studies, there were no significant differences in bronchodilator effect or hospital admissions between the two treatments. In
patients who require hospitalization, one study found that intermittent on-demand therapy led to a significantly shorter hospital stay, fewer nebulizations, and fewer palpitations when compared with intermittent therapy given every 4 hours. A reasonable approach to inhaled therapy
in exacerbations, therefore, would be the initial use of continuous therapy, followed by intermittent on-demand therapy for hospitalized patients. There is no evidence to support the routine use of intravenous beta2-agonists in patients with severe asthma exacerbations.
Epinephrine. A subcutaneous or intramuscular injection of epinephrine (adrenaline) may be indicated for acute treatment of anaphylaxis and angioedema, but is not routinely indicated during asthma exacerbations.
Additional bronchodilators.
Ipratropium bromide. A combination of nebulized beta2- agonist with an anticholinergic (ipratropium bromide) may produce better bronchodilation than either drug alone and should be administered before methylxanthines are considered. Combination beta2- agonist/anticholinergic therapy is associated with lower hospitalization rates and greater improvement in PEF and FEV1. Similar data have been reported in the pediatric literature . However, once children with asthma are hospitalized following intensive emergency department treatment, the addition of nebulized ipratropium bromide to nebulized beta2-agonist and systemic glucocorticosteroids appears to confer no extra benefit.
Theophylline. In view of the effectiveness and relative safety of rapid-acting beta2-agonists, theophylline has a minimal role in the management of acute asthma. Its use is associated with severe and potentially fatal side effects, particularly in those on long-term therapy with
sustained-release theophylline, and their bronchodilator effect is less than that of beta2-agonists. The benefit asadd-on treatment in adults with severe asthma exacerbations has not been demonstrated. However, in one study of children with near-fatal asthma, intravenous
theophylline provided additional benefit to patients also receiving an aggressive regimen of inhaled and intravenous beta2-agonists, inhaled ipatropium bromide, and intravenous systemic glucocorticosteroids.
Systemic glucocorticosteroids. Systemic glucocorticosteroids speed resolution of xacerbations and should be utilized in the all but the mildest exacerbations, especially if:
• The exacerbation develops even though the patient was already taking oral glucocorticosteroids
• Previous exacerbations required oral glucocorticosteroids.
cases. An oral glucocorticosteroid dose of 1 mg/kg daily is adequate for treatment of exacer-bations in children with mild persistent asthma. A 7-day course in adults has been found to be as effective as a 14-day course, and a 3- to 5-day course in children is usually considered appro-priate. Current evidence suggests that there is no benefit to tapering the dose of oral glucocorticosteroids, either in the short-term or over several weeks.
Inhaled glucocorticosteroids. Inhaled glucocorticosteroids are effective as part of therapy for asthma exacerbations. In one study, the combination of high-dose inhaled glucocorticosteroids and salbutamol in acute asthma provided greater bronchodilation than salbutamol alone, and conferred greater benefit than the addition of systemic glucocorticosteroids across all parameters, including hospitalizations, especially for patients with more severe attacks. Inhaled glucocorticosteroids can be as effective as oral glucocorticosteroids at preventing relapses. Patients discharged from the emergency department on prednisone and inhaled budesonide have a lower rate of relapse than
those on prednisone alone. A high-dose of inhaled glucocorticosteroid (2.4 mg budesonide daily in
four divided doses) achieves a relapse rate similar to 40 mg oral prednisone daily.
Cost is a significant factor in the use of such high-doses of inhaled glucocorticosteroids, and further studies are required to document their potential benefits, especially cost effectiveness, in acute asthma.
Magnesium. Intravenous magnesium sulphate (usually given as a single 2 g infusion over 20 minutes) is not recommended for routine use in asthma exacerbations, but can help reduce hospital admission rates in certain patients, including adults with FEV1 25-30% predicted at presentation, adults and children who fail to respond to initial treatment, and children whose FEV1 fails to improve
above 60% predicted after 1 hour of care. Nebulized salbutamol administered in isotonic magnesium sulfate provides greater benefit than if it is delivered in normal saline. Intravenous magnesium sulphate has not been studied in young children.
Helium oxygen therapy. A systematic survey of studies that have evaluated the effect of a combination of helium and oxygen, compared to helium alone, suggests there is no routine role for this intervention. It might be considered for patients who do not respond to standard therapy.
Leukotriene modifiers. There is little data to suggest a role for leukotriene modifiers in acute asthma.
Sedatives. Sedation should be strictly avoided during exacerbations of asthma because of the respiratory depressant effect of anxiolytic and hypnotic drugs. An association between the use of these drugs and avoidable asthma deaths has been demonstrated.
The foregoing are just the regimens listed (as recommended by GINA or the Global Initiative for Asthma), Global Strategy for Asthma Management and Prevention 2008 report.
For the whole report and comprehensive guideline ebook, visit http://www.ginasthma.com/index.asp?l1=1&l2=0

